Dr. Eugene Kwon has filed a patent application pertaining to B7-H1 as a prognostic marker in cancer.
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata
Associations with localized stage progression
Article first published online: 5 MAR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 8, pages 1499–1505, 15 April 2007
How to Cite
Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L. and Kwon, E. D. (2007), PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer, 109: 1499–1505. doi: 10.1002/cncr.22588
- Issue published online: 4 APR 2007
- Article first published online: 5 MAR 2007
- Manuscript Accepted: 3 JAN 2007
- Manuscript Revised: 19 DEC 2006
- Manuscript Received: 31 OCT 2006
- bladder cancer;
- programmed death ligand-1;
- urothelial carcinoma
PD-L1 (programmed death ligand 1, B7-H1) is a cell surface glycoprotein that can impair T-cell function. PD-L1 is aberrantly expressed by multiple human malignancies and has been shown to carry a highly unfavorable prognosis in patients with kidney cancer. The role of PD-L1 was evaluated as a mechanism for local stage progression in urothelial carcinoma (UC) of the bladder.
Using immunohistochemistry, PD-L1 expression was evaluated in a cohort of 280 high-risk UCs of the bladder. PD-L1 was modeled as a predictor of bladder cancer stage using ordinal logistic regression. Other covariates evaluated as potential confounders included age, gender, tumor grade, and lymphocytic infiltration. Further, PD-L1 was evaluated as a potential mechanism of bacillus Calmette-Guerin (BCG) failure in the subset of high-risk nonmuscle-invasive tumors that received this treatment.
PD-L1 expression was observed in 7% of pTa, 16% of pT1, 23% of pT2, 30% of pT3/4, and 45% of carcinoma in situ (CIS) tumors. PD-L1 expression was associated with high-grade tumors (odds ratio [OR] = 2.4, P = .009) and tumor infiltration by mononuclear cells (OR = 5.5, P = .004). We observed that the key determinants of stage progression in this cohort were World Health Organization/International Society of Urologic Pathology (WHO/ISUP) high-grade tumor pathology (OR = 4.77, 95% confidence interval [CI]: 2.73–8.34; P < .001) and PD-L1 expression (OR = 2.20, P = .012). PD-L1 expression was found to be extremely abundant in the BCG-induced bladder granulomata in 11 of 12 patients failing BCG treatment.
Collectively, these data indicate that tumor PD-L1 may facilitate localized stage-advancement of UC and attenuate responses to BCG immunotherapy by neutralizing T cells that normally guard against cancer invasion from the epithelium into the bladder musculature. Cancer 2007. © 2007 American Cancer Society.